DK1625847T3 - Medicinsk anvendelse af tetrahydrotriazolo[4,3-A]pyrazin - Google Patents

Medicinsk anvendelse af tetrahydrotriazolo[4,3-A]pyrazin

Info

Publication number
DK1625847T3
DK1625847T3 DK05077584.0T DK05077584T DK1625847T3 DK 1625847 T3 DK1625847 T3 DK 1625847T3 DK 05077584 T DK05077584 T DK 05077584T DK 1625847 T3 DK1625847 T3 DK 1625847T3
Authority
DK
Denmark
Prior art keywords
tetrahydrotriazolo
pyrazine
medical use
medical
Prior art date
Application number
DK05077584.0T
Other languages
Danish (da)
English (en)
Inventor
Scott D Edmondson
Michael H Fisher
Dooseop Kim
Malcolm Maccoss
Emma R Parmee
Ann E Weber
Jinyou Xu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23172273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1625847(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of DK1625847T3 publication Critical patent/DK1625847T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
DK05077584.0T 2001-07-06 2002-07-05 Medicinsk anvendelse af tetrahydrotriazolo[4,3-A]pyrazin DK1625847T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30347401P 2001-07-06 2001-07-06
EP02749813A EP1412357B1 (en) 2001-07-06 2002-07-05 Beta-amino tetrahydroimidazo(1,2-a)pyrazines and tetrahydrotriazolo(4,3-a)pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

Publications (1)

Publication Number Publication Date
DK1625847T3 true DK1625847T3 (da) 2010-10-18

Family

ID=23172273

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05077584.0T DK1625847T3 (da) 2001-07-06 2002-07-05 Medicinsk anvendelse af tetrahydrotriazolo[4,3-A]pyrazin
DK02749813T DK1412357T3 (da) 2001-07-06 2002-07-05 Beta-aminotetrahydroimidazo-(1,2-a)-pyraziner og tetrahydrotriazolo-(4,3-a)-pyraziner som dipeptidylpeptidaseinhibitorer til behandling eller forebyggelse af diabetes

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02749813T DK1412357T3 (da) 2001-07-06 2002-07-05 Beta-aminotetrahydroimidazo-(1,2-a)-pyraziner og tetrahydrotriazolo-(4,3-a)-pyraziner som dipeptidylpeptidaseinhibitorer til behandling eller forebyggelse af diabetes

Country Status (45)

Country Link
US (9) US7125873B2 (enExample)
EP (4) EP1625847B1 (enExample)
JP (1) JP3762407B2 (enExample)
KR (1) KR100606871B1 (enExample)
CN (2) CN1290848C (enExample)
AR (1) AR036114A1 (enExample)
AT (2) ATE471148T1 (enExample)
AU (1) AU2002320303B2 (enExample)
BE (1) BE2007C047I2 (enExample)
BG (1) BG108493A (enExample)
BR (1) BRPI0210866B8 (enExample)
CA (1) CA2450740C (enExample)
CR (1) CR7235A (enExample)
CY (3) CY2007019I2 (enExample)
DE (4) DE60236767D1 (enExample)
DK (2) DK1625847T3 (enExample)
DO (1) DOP2002000438A (enExample)
EA (2) EA006845B1 (enExample)
EC (1) ECSP044935A (enExample)
ES (2) ES2259713T3 (enExample)
FR (2) FR07C0041I2 (enExample)
GE (2) GEP20053734B (enExample)
HR (1) HRP20031098B1 (enExample)
HU (2) HU225695B1 (enExample)
IL (3) IL159109A0 (enExample)
IS (2) IS2218B (enExample)
JO (1) JO2230B1 (enExample)
LT (1) LTC1412357I2 (enExample)
LU (2) LUC91360I2 (enExample)
MA (1) MA27053A1 (enExample)
ME (1) ME00439B (enExample)
MX (1) MXPA04000018A (enExample)
MY (1) MY127961A (enExample)
NL (2) NL300287I2 (enExample)
NO (4) NO321999B1 (enExample)
NZ (1) NZ529833A (enExample)
PE (1) PE20030654A1 (enExample)
PL (1) PL196278B6 (enExample)
PT (2) PT1625847E (enExample)
RS (1) RS50737B (enExample)
SI (1) SI1412357T1 (enExample)
TW (1) TWI226331B (enExample)
UA (1) UA74912C2 (enExample)
WO (1) WO2003004498A1 (enExample)
ZA (1) ZA200309294B (enExample)

Families Citing this family (439)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006899A1 (en) * 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US7544511B2 (en) * 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
US20030176357A1 (en) * 1998-10-06 2003-09-18 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
DE69915514T2 (de) * 1998-12-31 2005-01-05 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Prenyltransferase-inhibitoren
ES2257555T3 (es) 2001-06-20 2006-08-01 MERCK & CO., INC. Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes.
JP2004535433A (ja) 2001-06-20 2004-11-25 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療用のジペプチジルペプチダーゼ阻害薬
DE60222667T2 (de) 2001-06-27 2008-07-17 Smithkline Beecham Corp. Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
AU2003219787A1 (en) * 2002-02-14 2003-09-04 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
DE60316416T2 (de) 2002-03-25 2008-06-26 Merck & Co., Inc. Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
ATE451369T1 (de) * 2002-07-15 2009-12-15 Merck & Co Inc Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ATE370141T1 (de) 2002-10-07 2007-09-15 Merck & Co Inc Antidiabetische heterocyclische beta- aminoverbindungen als inhibitoren von dipeptidylpeptidase
PL216527B1 (pl) * 2002-10-18 2014-04-30 Merck & Co Inc Związki ß-aminoheterocykliczne i kompozycja farmaceutyczna
ATE350374T1 (de) 2002-11-07 2007-01-15 Merck & Co Inc Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes
WO2004050022A2 (en) * 2002-12-04 2004-06-17 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1576134B1 (en) 2002-12-09 2013-03-06 Judith Kelleher-Andersson Method for discovering neurogenic agents
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
ES2311117T3 (es) * 2002-12-10 2009-02-01 Novartis Ag Combinacion de un inhibidor de dpp-iv y un compuesto ppar-alfa.
AU2003297219A1 (en) * 2002-12-20 2004-07-22 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
AU2004206812A1 (en) * 2003-01-17 2004-08-05 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2513684A1 (en) * 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AR043443A1 (es) * 2003-03-07 2005-07-27 Merck & Co Inc Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios
AR043505A1 (es) * 2003-03-18 2005-08-03 Merck & Co Inc Preparacion de beta-cetoamidas e intermediarios de reaccion
AR043515A1 (es) * 2003-03-19 2005-08-03 Merck & Co Inc Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica
WO2004085661A2 (en) * 2003-03-24 2004-10-07 Merck & Co., Inc Process to chiral beta-amino acid derivatives
US7550590B2 (en) * 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2004087650A2 (en) * 2003-03-27 2004-10-14 Merck & Co. Inc. Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
ZA200508439B (en) 2003-05-05 2007-03-28 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
DE602004023932D1 (de) * 2003-05-14 2009-12-17 Merck & Co Inc 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
ATE463492T1 (de) * 2003-06-06 2010-04-15 Merck Sharp & Dohme Kondensierte indole als dipeptidyl-peptidase- hemmer zur behandlung oder prävention von diabetes
EP1635832A2 (en) * 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
EP1638950A4 (en) * 2003-06-17 2010-06-30 Merck Sharp & Dohme CYCLOHEXYLGLYCIN DERIVATIVES AS DIPEPTIDYLPEPTIDASEINHIBITORS FOR THE TREATMENT OF BZW. PREVENTION OF DIABETES
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005007658A2 (en) 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
DE602004021603D1 (de) * 2003-07-25 2009-07-30 Conjuchem Biotechnologies Inc Insulinderivative mit langanhaltender wirkung und verfahren zu deren herstellung
CA2533893A1 (en) * 2003-07-31 2005-02-10 Merck & Co., Inc. Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2004268024B2 (en) * 2003-09-02 2007-07-12 Merck Sharp & Dohme Llc Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
JP2007513058A (ja) * 2003-09-08 2007-05-24 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2005028438A1 (ja) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
US20070021430A1 (en) * 2003-09-23 2007-01-25 Chen Alex M Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
EP1684786A4 (en) * 2003-10-24 2007-12-12 Merck & Co Inc IMPROVING THE MIRROR OF THE GROWTH HORMONE WITH A DIPEPTIDYL PEPTIDASE IV INHIBITOR AND A GROWTH HORMONE SECRETAGOG
NZ546887A (en) 2003-11-03 2009-04-30 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
EP1682120A4 (en) * 2003-11-04 2009-05-27 Merck & Co Inc CAPACITATED PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDAS IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
NZ547752A (en) * 2003-11-12 2009-12-24 Phenomix Corp Heterocyclic boronic acid compounds for inhibiting dipeptidyl peptidase-IV
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
AU2004290897B2 (en) 2003-11-17 2009-02-26 Novartis Ag Use of dipeptidyl peptidase IV inhibitors
WO2005072530A1 (en) * 2004-01-16 2005-08-11 Merck & Co., Inc. Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
ES2899417T3 (es) 2004-01-20 2022-03-11 Novartis Ag Formulación y proceso de compresión directa
PL1712547T3 (pl) * 2004-02-05 2012-04-30 Kyorin Seiyaku Kk Pochodna bicykloestrowa
EP1713780B1 (en) 2004-02-05 2012-01-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
KR20060129021A (ko) * 2004-02-18 2006-12-14 교린 세이야꾸 가부시키 가이샤 비시클로아미드 유도체
JP4689599B2 (ja) * 2004-02-27 2011-05-25 杏林製薬株式会社 ビシクロ誘導体
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102134230B (zh) 2004-03-15 2019-06-28 武田药品工业株式会社 二肽基肽酶抑制剂
WO2005097759A1 (en) 2004-03-29 2005-10-20 Merck & Co., Inc. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
TW200602293A (en) * 2004-04-05 2006-01-16 Merck & Co Inc Process for the preparation of enantiomerically enriched beta amino acid derivatives
CA2564264A1 (en) * 2004-05-04 2005-11-17 Merck & Co., Inc. 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CN1960990A (zh) * 2004-05-18 2007-05-09 默克公司 作为用于治疗或预防糖尿病的二肽基肽酶－ⅳ抑制剂的环己基丙氨酸衍生物
JP2008501714A (ja) * 2004-06-04 2008-01-24 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
AU2005265148B2 (en) * 2004-06-21 2011-01-20 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CA2574418A1 (en) * 2004-07-23 2006-02-02 Susan Marie Royalty Peptidase inhibitors
TW200608967A (en) 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
ATE472531T1 (de) 2004-08-06 2010-07-15 Merck Sharp & Dohme Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
CA2576465A1 (en) 2004-08-23 2006-03-02 Merck & Co., Inc. Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006022428A1 (ja) * 2004-08-26 2006-03-02 Takeda Pharmaceutical Company Limited 糖尿病治療剤
AR050615A1 (es) 2004-08-27 2006-11-08 Novartis Ag Composiciones farmaceuticas para la administracion oral
US7612072B2 (en) 2004-09-15 2009-11-03 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US20060063719A1 (en) * 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
AU2005292134B2 (en) 2004-10-01 2010-12-23 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
AU2005293266B2 (en) * 2004-10-12 2011-09-29 Glenmark Pharmaceuticals S.A. Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7691629B2 (en) * 2004-11-17 2010-04-06 Neuralstem, Inc. Transplantation of human neural cells for treatment of neurodegenerative conditions
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
EP1874308A1 (en) 2005-03-08 2008-01-09 Nycomed GmbH Roflumilast for the treatment of diabetes mellitus
TWI357902B (en) 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth
JP2008540426A (ja) * 2005-05-02 2008-11-20 メルク エンド カムパニー インコーポレーテッド 糖尿病及び肥満の治療のためのジペプチジルペプチダーゼｉｖ阻害薬及びカンナビノイドｃｂ１受容体拮抗薬の組み合わせ
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7906649B2 (en) * 2005-05-25 2011-03-15 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
WO2006129826A1 (ja) 2005-05-30 2006-12-07 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
JP4915833B2 (ja) * 2005-07-01 2012-04-11 雪印メグミルク株式会社 ジペプチジルペプチダーゼｉｖ阻害剤
US8076514B2 (en) * 2005-07-20 2011-12-13 Eli Lilly And Company Phenyl compounds and their use in the treatment of Type II diabetes
US8106090B2 (en) * 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
ATE432259T1 (de) * 2005-07-20 2009-06-15 Lilly Co Eli Pyridinderivate als dipeptedyl-peptidase-hemmer
US20090221592A1 (en) * 2005-07-25 2009-09-03 Ellison Martha E Dodecylsulfate Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1916239A4 (en) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd PYRIDOLVERBINDUNG
EP1921065B1 (en) 2005-08-24 2010-10-20 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
CA2620223A1 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE
GEP20135791B (en) * 2005-09-14 2013-03-25 Takeda Pharmaceutical Use of dipeptidyl peptidase inhibitors
ATE532518T1 (de) 2005-09-14 2011-11-15 Takeda Pharmaceutical Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007050485A2 (en) * 2005-10-25 2007-05-03 Merck & Co., Inc. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
WO2007049798A1 (ja) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. 新規ベンゾオキサチイン誘導体
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
AU2006333151B2 (en) * 2005-12-16 2010-03-04 Merck Sharp & Dohme Llc Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
GB0526291D0 (en) * 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
JP5094416B2 (ja) * 2005-12-28 2012-12-12 武田薬品工業株式会社 糖尿病治療剤
AP2008004537A0 (en) * 2005-12-30 2008-08-31 Ranbaxy Lab Ltd Muscarinic receptor antagonists
US20090156465A1 (en) 2005-12-30 2009-06-18 Sattigeri Jitendra A Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
AU2007208405B2 (en) * 2006-01-25 2011-05-26 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
AU2007224066B2 (en) * 2006-03-08 2011-10-27 Kyorin Pharmaceutical Co., Ltd. Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007112368A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
CN103323606A (zh) * 2006-04-11 2013-09-25 艾尼纳制药公司 使用gpr119受体鉴定可用于增加个体骨质量的化合物的方法
KR20080109915A (ko) 2006-04-11 2008-12-17 노파르티스 아게 유기 화합물
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
JP5323684B2 (ja) 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
NZ574710A (en) 2006-09-07 2012-02-24 Nycomed Gmbh Combination treatment comprising the PDE4 inhibitor Compound A ((2R,4aR, 10bR)6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1 ,2,3,4,4a,10b-hexahydrophenanthridin-2-ol) for diabetes mellitus
SI2073810T1 (sl) * 2006-09-13 2011-12-30 Takeda Pharmaceutical Uporaba 2-6(3-amino-piperidin-1-il)-3-metil-2,4-diokso-3,4-dihidro-2H-pirimidin -1-ilmetil-4-fluoro-benzonitrila za zdravljenje diabetesa, raka, avtoimunskih motenj in infekcije s HIV
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
CA2770486C (en) 2006-09-22 2014-07-15 Merck Sharp & Dohme Corp. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
KR20080071476A (ko) * 2007-01-30 2008-08-04 주식회사 엘지생명과학 신규한 디펩티딜 펩티데이즈 ｉｖ(ｄｐｐ-ｉｖ) 저해제
KR101486091B1 (ko) 2007-02-01 2015-01-23 다케다 야쿠힌 고교 가부시키가이샤 알로그립틴 및 피오글리타존을 포함하는 고형 제제
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
JPWO2008114857A1 (ja) * 2007-03-22 2010-07-08 杏林製薬株式会社 アミノアセチルピロリジンカルボニトリル誘導体の製造方法
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
US8927504B2 (en) 2007-04-03 2015-01-06 Mitsubishi Tanabe Pharma Corporation Combined use of dipeptidyl peptidase 4 inhibitor and sweetener
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008248186B2 (en) 2007-05-07 2014-02-06 Merck Sharp & Dohme Corp. Method of treatment using fused aromatic compounds having anti-diabetic activity
US7820666B2 (en) * 2007-05-08 2010-10-26 Concert Pharmaceuticals, Inc. Tetrahydrotriazolopyrazine derivatives and uses thereof
CA2963857A1 (en) 2007-06-04 2008-12-11 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CN101318922B (zh) * 2007-06-08 2010-11-10 上海阳帆医药科技有限公司 一类二肽基肽酶抑制剂、合成方法和用途
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
CN101397300B (zh) * 2007-09-04 2011-04-27 山东轩竹医药科技有限公司 二肽酶-ⅳ抑制剂衍生物
US20090076013A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched sitagliptin
CN101417999A (zh) * 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
US8334385B2 (en) * 2007-11-02 2012-12-18 Glenmark Generics Limited Process for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof
US20090192326A1 (en) * 2007-11-13 2009-07-30 Nurit Perlman Preparation of sitagliptin intermediate
CN101903390A (zh) * 2007-12-20 2010-12-01 雷迪博士实验室有限公司 制备西他列汀及其药学上可接受的盐的方法
UA103181C2 (ru) * 2007-12-21 2013-09-25 Ел Джи Лайф Сайєнсіз, Лтд. Соединения, которые ингибируют дипептидилпептидазу-iv и фармацевтическая композиция, которая содержит их как активный агент
CN101468988A (zh) 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
EA018612B1 (ru) * 2008-01-24 2013-09-30 Панацеа Биотек Лимитед Новые гетероциклические соединения
CA2713361A1 (en) * 2008-02-05 2009-08-13 Merck Sharp & Dohme Corp. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
EP2259676A4 (en) * 2008-03-04 2011-03-16 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE IV HEMMER
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
US20090247532A1 (en) * 2008-03-28 2009-10-01 Mae De Ltd. Crystalline polymorph of sitagliptin phosphate and its preparation
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
US20090264476A1 (en) * 2008-04-18 2009-10-22 Mckelvey Craig CB-1 receptor modulator formulations
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
US8003672B2 (en) * 2008-04-21 2011-08-23 Merck Sharp & Dohme Corp. CB-1 receptor modulator formulations
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2301936A1 (en) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
EP2650299A1 (en) 2008-07-03 2013-10-16 Ratiopharm GmbH Crystalline salts of sitagliptin
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US20100069637A1 (en) * 2008-07-29 2010-03-18 Medichem S.A. CRYSTALLINE SALT FORMS OF A 5,6,7,8-TETRAHYDRO-1,2,4-TRIAZOLO[4,3-a]PYRAZINE DERIVATIVE
WO2010013595A1 (ja) 2008-07-30 2010-02-04 萬有製薬株式会社 ５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
CN102119139A (zh) * 2008-08-07 2011-07-06 杏林制药株式会社 二环[2.2.2]辛胺衍生物的制造方法
CA2733778A1 (en) * 2008-08-14 2010-02-18 Hiroshi Uchida Stabilized pharmaceutical composition
EP2326326B1 (en) * 2008-08-15 2019-10-09 Boehringer Ingelheim International GmbH Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
WO2010032264A2 (en) * 2008-08-27 2010-03-25 Cadila Healthcare Limited Improved process for preparation of (2r)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin- 7(8h)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine & new impurities in preparation thereof
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
JP2012504630A (ja) 2008-10-03 2012-02-23 シェーリング コーポレイション グルカゴン受容体アンタゴニストとしてのスピロイミダゾロン誘導体
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101054911B1 (ko) * 2008-10-17 2011-08-05 동아제약주식회사 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2350010B1 (en) 2008-10-30 2014-03-26 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
JP5514831B2 (ja) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療のための置換二環式アミン
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
ES2603215T3 (es) * 2008-12-31 2017-02-24 Chiral Quest, Inc. Procedimiento y productos intermedios para la preparación de derivados de beta-aminoácidos N-acilados-4-arilo
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
US8404727B2 (en) * 2009-01-07 2013-03-26 Glenmark Pharmaceuticals S.A. Pharmaceutical composition that includes a dipeptidyl peptidase-IV inhibitor
SG172924A1 (en) 2009-01-09 2011-08-29 Orchid Res Lab Ltd Dipeptidyl peptidase iv inhibitors
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
EP2218721A1 (en) * 2009-02-11 2010-08-18 LEK Pharmaceuticals d.d. Novel salts of sitagliptin
US20110046076A1 (en) 2009-02-13 2011-02-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
NZ594044A (en) 2009-02-13 2014-08-29 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
EP2223923A1 (en) 2009-02-25 2010-09-01 Esteve Química, S.A. Process for the preparation of a chiral beta aminoacid derivative and intermediates thereof
CN101824036A (zh) * 2009-03-05 2010-09-08 上海恒瑞医药有限公司 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
SG174973A1 (en) 2009-03-30 2011-11-28 Dong A Pharm Co Ltd Improved method for manufacturing dipeptidyl peptidase-iv inhibitor and intermediate
CN102378751B (zh) 2009-03-30 2014-08-20 东亚St株式会社 用于制备二肽基肽酶-iv抑制剂和中间体的改进方法
CN101849944A (zh) * 2009-03-31 2010-10-06 江苏恒瑞医药股份有限公司 治疗2型糖尿病的药物组合物
WO2010122578A2 (en) * 2009-04-20 2010-10-28 Msn Laboratories Limited Process for the preparation of sitagliptin and its intermediates
AU2010247193B2 (en) * 2009-05-11 2016-05-19 Tianish Laboratories Private Limited Sitagliptin synthesis
CN101899047B (zh) * 2009-05-26 2016-01-20 盛世泰科生物医药技术(苏州)有限公司 作为二肽基肽酶抑制剂用于治疗或预防糖尿病的β-氨基四氢吡嗪、四氢嘧啶和四氢吡啶
CN101899048B (zh) * 2009-05-27 2013-04-17 上海恒瑞医药有限公司 (R)-7-[3-氨基-4-(2,4,5-三氟-苯基)-丁酰]-3-三氟甲基-5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸甲酯的盐
US8470773B2 (en) 2009-06-12 2013-06-25 Merck Sharp & Dohme Corp. Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
IT1395596B1 (it) 2009-06-30 2012-10-16 Dipharma Francis Srl Procedimento per la preparazione di sitagliptin
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
AR077463A1 (es) 2009-07-09 2011-08-31 Irm Llc Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
US20120189611A1 (en) 2009-08-03 2012-07-26 Kaneka Corporation Dipeptidyl peptidase-4 inhibitor
WO2011018494A1 (de) 2009-08-13 2011-02-17 Sandoz Ag Kristalline verbindung von 7-[(3r)-3-amino-1-oxo-4- (2, 4, 5-trifluorphenyl) butyl]-5, 6, 7, 8-tetrahydro-3-(tri fluormethyl)-1, 2, 4-triazolo[4,3-a]pyrazin
US8552022B2 (en) 2009-08-13 2013-10-08 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
RU2550508C2 (ru) 2009-09-02 2015-05-10 Мерк Шарп И Доум Корп. Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-iv для лечения или предупреждения диабета
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP2295083A1 (de) 2009-09-15 2011-03-16 Ratiopharm GmbH Pharmazeutische Zusammensetzung mit den Wirkstoffen Metformin und Sitagliptin oder Vildagliptin
CN102030683B (zh) * 2009-09-27 2013-07-31 浙江九洲药业股份有限公司 西他列汀中间体及其制备方法和用途
EP2308847B1 (en) 2009-10-09 2014-04-02 EMC microcollections GmbH Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases
EP2501685A1 (en) 2009-11-16 2012-09-26 Mellitech [1,5]-diazocin derivatives
KR20190071840A (ko) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
JP5540454B2 (ja) 2009-12-30 2014-07-02 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド ジペプチジルペプチダーゼ阻害剤
KR101156587B1 (ko) 2010-02-19 2012-06-20 한미사이언스 주식회사 시타글립틴의 제조방법 및 이에 사용되는 아민염 중간체
WO2011103256A1 (en) 2010-02-22 2011-08-25 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
CZ303113B6 (cs) 2010-03-16 2012-04-11 Zentiva, K.S. Zpusob prípravy sitagliptinu
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
WO2011123641A1 (en) 2010-03-31 2011-10-06 Teva Pharmaceutical Industries Ltd. Solid state forms of sitagliptin salts
PH12012501974A1 (en) * 2010-04-05 2013-01-07 Cadila Pharmaceuticals Ltd Novel hypoglycemic compounds
US20130023494A1 (en) 2010-04-06 2013-01-24 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
ES2629624T3 (es) * 2010-04-28 2017-08-11 Sun Pharmaceutical Industries Limited Proceso para la preparación de derivados quirales de la beta amino carboxamida
MX366325B (es) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
US8980929B2 (en) 2010-05-21 2015-03-17 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
CN102260265B (zh) 2010-05-24 2015-09-02 上海阳帆医药科技有限公司 六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途
EP2392575A1 (en) 2010-06-04 2011-12-07 LEK Pharmaceuticals d.d. A novel synthetic approach to ß-aminobutyryl substituted compounds
EP2576563B1 (en) * 2010-06-04 2016-05-11 LEK Pharmaceuticals d.d. A NOVEL SYNTHETIC APPROACH TO ß-AMINOBUTYRYL SUBSTITUTED COMPOUNDS
EP2397141A1 (en) 2010-06-16 2011-12-21 LEK Pharmaceuticals d.d. Process for the synthesis of beta-amino acids and derivatives thereof
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
EP2407469A1 (en) 2010-07-13 2012-01-18 Chemo Ibérica, S.A. Salt of sitagliptin
EP2423178A1 (en) 2010-07-28 2012-02-29 Chemo Ibérica, S.A. Process for the production of sitagliptin
US9540611B2 (en) 2010-07-28 2017-01-10 Neuralstem, Inc. Methods for treating and/or reversing neurodegenerative diseases and/or disorders
EP2418196A1 (en) * 2010-07-29 2012-02-15 IMTM GmbH Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
US8742110B2 (en) 2010-08-18 2014-06-03 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
US20130158265A1 (en) 2010-08-27 2013-06-20 Dhananjay Govind Sathe Sitagliptin, salts and polymorphs thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2012035549A2 (en) 2010-09-13 2012-03-22 Panacea Biotec Ltd An improved process for the synthesis of beta amino acid derivatives
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
CN103228658A (zh) 2010-10-08 2013-07-31 卡迪拉保健有限公司 用于通过酶促转化制备西他列汀的中间体的方法
WO2012049566A1 (en) 2010-10-14 2012-04-19 Japan Tobacco Inc. Combination therapy for use in treating diabetes
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102485718B (zh) 2010-12-03 2014-03-26 浙江海翔药业股份有限公司 西他列汀的中间体及其制备方法
US8691832B2 (en) 2010-12-06 2014-04-08 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
WO2012076973A2 (en) 2010-12-09 2012-06-14 Aurobindo Pharma Limited Novel salts of dipeptidyl peptidase iv inhibitor
TWI494313B (zh) * 2010-12-29 2015-08-01 Jiangsu Hengrui Medicine Co 治療包括人類之哺乳動物中第２型糖尿病的醫藥組成物
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
WO2013103384A1 (en) 2012-01-06 2013-07-11 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
WO2012094636A2 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
KR101290029B1 (ko) * 2011-01-20 2013-07-30 에스티팜 주식회사 시타글립틴의 중간체 제조방법
RS54735B1 (sr) 2011-01-31 2016-10-31 Cadila Healthcare Ltd Tretman za lipodistrofiju
BR122021002201A8 (pt) 2011-02-25 2023-04-11 Merck Sharp & Dohme Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
KR102034748B1 (ko) 2011-03-01 2019-10-21 시너지 파마슈티컬즈 인코포레이티드 구아닐레이트 사이클라제 c 작용제의 제조 방법
JP2014510071A (ja) 2011-03-03 2014-04-24 カディラ・ヘルスケア・リミテッド Ｄｐｐ−ｉｖ阻害剤の新規な塩
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
WO2012131005A1 (en) 2011-03-29 2012-10-04 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition of sitagliptin
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012138845A1 (en) 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EP2508506A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Preparation of sitagliptin intermediates
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101369584B1 (ko) 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
CN102757431B (zh) * 2011-04-24 2016-03-30 浙江华海药业股份有限公司 一种合成西他列汀的新方法
ITMI20110765A1 (it) 2011-05-05 2012-11-06 Chemo Iberica Sa Processo per la produzione di sitagliptina
US8524936B2 (en) 2011-05-18 2013-09-03 Milan Soukup Manufacturing process for sitagliptin from L-aspartic acid
US9359385B2 (en) * 2011-05-27 2016-06-07 Lek Pharmaceuticals D.D. Preparation of sitagliptin intermediates
EP2527320A1 (en) 2011-05-27 2012-11-28 LEK Pharmaceuticals d.d. Preparation of Sitagliptin Intermediates
JP2014518890A (ja) 2011-06-02 2014-08-07 インターベット インターナショナル ベー． フェー． イミダゾール誘導体
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
AR086675A1 (es) * 2011-06-14 2014-01-15 Merck Sharp & Dohme Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
JP2014517036A (ja) 2011-06-16 2014-07-17 メルク・シャープ・アンド・ドーム・コーポレーション 置換シクロプロピル化合物、そのような化合物を含有する組成物および治療方法
WO2013001514A1 (en) 2011-06-29 2013-01-03 Ranbaxy Laboratories Limited Solid dispersions of sitagliptin and processes for their preparation
CA2838738A1 (en) 2011-06-29 2013-01-03 Merck Sharp & Dohme Corp. Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
US20150051213A1 (en) 2011-06-30 2015-02-19 Suresh Babu Jayachandra Novel salts of sitagliptin
EP2729468A4 (en) 2011-07-05 2015-03-18 Merck Sharp & Dohme Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
EA024688B1 (ru) * 2011-07-27 2016-10-31 ФАРМА ДжРС, Д.О.О. Способ получения ситаглиптина и его фармацевтически приемлемых солей
EP2753328A1 (en) 2011-09-07 2014-07-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dpp-iv inhibitor formulations
US9422266B2 (en) 2011-09-30 2016-08-23 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
ES2487271T3 (es) 2011-10-06 2014-08-20 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulaciones de dosificación sólidas inhibidoras de DPP-IV
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN103649090A (zh) 2011-10-14 2014-03-19 劳乐斯实验室私营有限公司 新的西他列汀盐、其制备方法及其药物组合物
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9018200B2 (en) 2011-10-24 2015-04-28 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as GPR119 agonists
CN102603749B (zh) * 2011-10-27 2017-02-08 浙江华海药业股份有限公司 一种西他列汀中间体的合成方法
WO2013065066A1 (en) 2011-11-02 2013-05-10 Cadila Healthcare Limited Processes for preparing 4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro [l,2,41-triazolo[43-a]pyrazin-7(8h)-yl]-l-(2,4,5- trifluorophenyl)butan-2-amine
WO2013068328A1 (en) 2011-11-07 2013-05-16 Intervet International B.V. Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
WO2013068439A1 (en) 2011-11-09 2013-05-16 Intervet International B.V. 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
JP6101279B2 (ja) 2011-11-15 2017-03-22 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｇｐｒ１１９アゴニストとして有用な置換シクロプロピル化合物
US20140350023A1 (en) 2011-12-08 2014-11-27 Ranbaxy Laboratories Limited Amorphous form of sitagliptin salts
SG10201901922VA (en) 2012-01-06 2019-04-29 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
EP2615080A1 (en) 2012-01-12 2013-07-17 LEK Pharmaceuticals d.d. Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof
WO2013122920A1 (en) 2012-02-17 2013-08-22 Merck Sharp & Dohme Corp. Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
ES2421956B1 (es) 2012-03-02 2014-09-29 Moehs Ibérica S.L. Nueva forma cristalina de sulfato de sitagliptina
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20150057220A1 (en) 2012-04-16 2015-02-26 Kaneq Pharma Inc. Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
TWI469785B (zh) 2012-04-25 2015-01-21 Inovobiologic Inc 用於治療代謝性疾病之膳食纖維組成物
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2674432A1 (en) 2012-06-14 2013-12-18 LEK Pharmaceuticals d.d. New synthetic route for the preparation of ß aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha]pyrazin-7-yl compounds
EP2874626A4 (en) 2012-07-23 2016-03-23 Merck Sharp & Dohme TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
WO2014018350A1 (en) 2012-07-23 2014-01-30 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-iv inhibitors
AU2013296470B2 (en) 2012-08-02 2016-03-17 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2882752A1 (en) 2012-08-08 2015-06-17 Cipla Limited Process for the preparation of sitagliptin and intermediate compounds
CN102898387B (zh) * 2012-09-26 2015-01-07 浙江工业大学 管道化连续生产n-[(2z)-哌嗪-2-亚基]-2,2,2-三氟乙酰肼的方法
TWI500613B (zh) 2012-10-17 2015-09-21 Cadila Healthcare Ltd 新穎之雜環化合物
CN103788070B (zh) * 2012-10-26 2017-10-20 南京华威医药科技开发有限公司 Dpp‑4抑制剂类多聚物
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CZ306115B6 (cs) * 2012-12-04 2016-08-10 Zentiva, K.S. Způsob přípravy derivátů kyseliny 3-amino-4-(2,4,5-trifluorfenyl)-butanové
CN103319487B (zh) * 2013-01-10 2015-04-01 药源药物化学（上海）有限公司 西格列汀的制备方法及其中间体
EP2769712A1 (en) 2013-02-21 2014-08-27 Siegfried International AG Pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014127745A1 (zh) * 2013-02-22 2014-08-28 成都先导药物开发有限公司 一种抑制dpp-iv的化合物及其中间体
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
IN2013MU00916A (enExample) 2013-03-20 2015-06-26 Cadila Healthcare Ltd
KR101617812B1 (ko) 2013-04-22 2016-05-03 카딜라 핼쓰캐어 리미티드 비알콜성 지방간 질환을 위한 신규 조성물
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015001568A2 (en) * 2013-07-01 2015-01-08 Laurus Labs Private Limited Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (enExample) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10517892B2 (en) 2013-10-22 2019-12-31 Medtronic Minimed, Inc. Methods and systems for inhibiting foreign-body responses in diabetic patients
CZ2013842A3 (cs) 2013-11-01 2015-05-13 Zentiva, K.S. Stabilní polymorf soli (2R)-4-oxo-4-[3-(trifluorometyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorofenyl)butan-2-aminu s kyselinou L-vinnou
MX2016005995A (es) 2013-11-05 2016-08-17 Ben-Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de diabetes y complicaciones de la enfermedad derivadas de la misma.
CN103626775B (zh) * 2013-12-02 2015-05-20 南京华威医药科技开发有限公司 具有二嗪结构的dpp-4抑制剂
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
IN2014MU00212A (enExample) 2014-01-21 2015-08-28 Cadila Healthcare Ltd
US10065945B2 (en) 2014-01-24 2018-09-04 Merck Sharp & Dohme Corp. Isoquinoline derivatives as MGAT2 inhibitors
IN2014MU00651A (enExample) 2014-02-25 2015-10-23 Cadila Healthcare Ltd
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2015145333A1 (en) 2014-03-26 2015-10-01 Sun Pharmaceutical Industries Limited Process for the preparation of sitagliptin and its intermediate
MX374598B (es) 2014-04-17 2025-03-06 Merck Sharp & Dohme Llc Complejo de tanato de sitagliptina.
WO2015162506A1 (en) 2014-04-21 2015-10-29 Suven Life Sciences Limited Process for the preparation of sitagliptin and novel intermediates
WO2015170340A2 (en) * 2014-05-06 2015-11-12 Laurus Labs Private Limited Novel polymorphs of sitagliptin hydrochloride, processes for its preparation and pharmaceutical composition thereof
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9862725B2 (en) 2014-07-21 2018-01-09 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-IV inhibitors
CN104140430B (zh) * 2014-08-08 2016-07-13 广东东阳光药业有限公司 一种异构体的消旋方法
US10100042B2 (en) 2014-08-08 2018-10-16 Merck Sharp & Dohme Corp. [5,6]—fused bicyclic antidiabetic compounds
EP3177282B1 (en) 2014-08-08 2021-10-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3177287B1 (en) 2014-08-08 2022-02-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
WO2016046679A1 (en) * 2014-09-28 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of diabetes and pre-diabetes
CN107148275A (zh) 2014-10-20 2017-09-08 神经干细胞公司 包含编码生长因子的外源多核苷酸的稳定的神经干细胞及其使用方法
EP3242666B9 (en) 2015-01-06 2024-12-25 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
MX2017009004A (es) 2015-01-08 2018-03-15 Lee Pharma Ltd Nuevo proceso para la preparacion del inhibidor de la enzima dipeptidil peptidasa-4 (dpp-4).
CZ27930U1 (cs) 2015-01-13 2015-03-10 Zentiva, K.S. Krystalická modifikace 3 L-vínanu (3R)-3-amino-1-[3-(trifluormethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorfenyl)butan-1-onu
CZ27898U1 (cs) 2015-01-13 2015-03-02 Zentiva, K.S. Krystalická modifikace 2 L-vínanu (3R)-3-amino-1-[3-(trifluormethyl)-6,8-dihydro-5H-[1,2,4,]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorfenyl)butan-1-onu
KR20220070057A (ko) 2015-03-09 2022-05-27 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
US9447015B1 (en) * 2015-04-15 2016-09-20 Valent Biosciences Corporation (S)-2′-vinyl-abscisic acid derivatives
KR101772898B1 (ko) 2015-06-11 2017-08-31 동방에프티엘(주) 시타글립틴의 개선된 제조방법
KR101709127B1 (ko) 2015-06-16 2017-02-22 경동제약 주식회사 Dpp-iv 억제제의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 dpp-iv 억제제의 제조방법
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
CN105017260B (zh) * 2015-07-30 2017-04-19 新发药业有限公司 一种西他列汀中间体三唑并吡嗪衍生物的制备方法
WO2017020974A1 (en) 2015-08-03 2017-02-09 Institut Pasteur Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
EP3347462A4 (en) * 2015-09-09 2019-08-14 Warren C. Lau METHOD, COMPOSITIONS AND USE OF NOVEL FYN KINASEINHIBITORS
KR20170036288A (ko) 2015-09-24 2017-04-03 주식회사 종근당 시타글립틴의 신규염 및 이의 제조방법
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
ES2638266T3 (es) * 2015-10-22 2017-10-19 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Procedimiento mejorado para la preparación de triazol y una de sus sales
US10450309B2 (en) 2015-11-30 2019-10-22 Merch Sharp & Dohme Corp. Aryl sulfonamides as BLT1 antagonists
EP3383868B1 (en) 2015-11-30 2022-10-05 Merck Sharp & Dohme LLC Aryl sulfonamides as blt1 antagonists
KR102405278B1 (ko) 2016-04-22 2022-06-07 악셀레론 파마 인코포레이티드 Alk7 결합 단백질 및 이들의 용도
WO2017201683A1 (en) 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
WO2018034917A1 (en) 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
EP3496716B1 (en) 2016-08-15 2021-11-03 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
CN106124667B (zh) * 2016-08-29 2018-07-31 上海应用技术学院 一种分离测定西格列汀有关物质的方法
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
MX2016016260A (es) 2016-12-08 2018-06-07 Alparis Sa De Cv Nuevas formas solidas de sitagliptina.
MX382765B (es) 2016-12-09 2025-03-13 Zydus Lifesciences Ltd Tratamiento para la colangitis biliar primaria.
WO2018107415A1 (en) 2016-12-15 2018-06-21 Merck Sharp & Dohme Corp. Hydroxy isoxazole compounds useful as gpr120 agonists
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
US11197949B2 (en) 2017-01-19 2021-12-14 Medtronic Minimed, Inc. Medication infusion components and systems
US10047094B1 (en) 2017-02-10 2018-08-14 F.I.S.—Fabbrica Italiana Sintetici S.p.A. Process for the preparation of triazole and salt thereof
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
WO2018162722A1 (en) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Dpp-4 inhibitors for use in treating bone fractures
SG11201909046XA (en) 2017-04-03 2019-10-30 Coherus Biosciences Inc PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
CA3059327A1 (en) 2017-04-24 2018-11-01 Novartis Ag Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8h)-yl)ethanone and combinations thereof
US11096890B2 (en) 2017-09-29 2021-08-24 Merck Sharp & Dohme Corp. Chewable dosage forms containing sitagliptin and metformin
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
KR20190060235A (ko) 2017-11-24 2019-06-03 제일약품주식회사 시타글립틴 캄실산염의 제조방법
TR201722603A2 (tr) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari
CN108586346B (zh) 2018-05-10 2019-10-01 北京富盛嘉华医药科技有限公司 一种生物催化合成西他列汀及其中间体的方法
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
TW202045476A (zh) 2019-02-13 2020-12-16 美商默沙東藥廠 5-烷基吡咯啶食慾素受體促效劑
EP3923933A4 (en) 2019-02-13 2022-08-17 Merck Sharp & Dohme Corp. PYRROLIDINOREXINE RECEPTOR AGONISTS
WO2020205688A1 (en) 2019-04-04 2020-10-08 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
EP4045048A4 (en) 2019-10-14 2023-05-24 Santa Farma Ilaç Sanayi A.S. ORAL FORMULATIONS COMPRISING SITAGLIPTIN HCI MONOHYDRATE WITH ENHANCED PHARMACEUTICAL CHARACTERISTICS
KR20210057603A (ko) 2019-11-12 2021-05-21 제이투에이치바이오텍 (주) 시타글립틴의 제조방법
AU2021329805B2 (en) 2020-08-18 2024-02-29 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists
EP4211139A4 (en) * 2020-09-10 2024-12-18 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
KR102589305B1 (ko) 2021-04-22 2023-10-16 주식회사 메디켐코리아 시타글립틴 인산염의 개선된 제조방법
CN113979896A (zh) * 2021-11-18 2022-01-28 浙江永太手心医药科技有限公司 一种西格列汀杂质i及其制备方法
EP4469459A1 (en) 2022-01-24 2024-12-04 Zaklady Farmaceutyczne Polpharma S.A. Process for preparing crystalline sitagliptin hydrochloride monohydrate
EP4604931A1 (en) 2022-10-21 2025-08-27 Merck Sharp & Dohme LLC Compositions of a dipeptidyl peptidase-iv inhibitor and an antioxidant
WO2024121301A1 (en) 2022-12-09 2024-06-13 Krka, D.D., Novo Mesto Process for the preparation of sitagliptin
CN116064457B (zh) 2022-12-16 2025-08-19 浙江工业大学 一种ω-转氨酶突变体及其应用
EP4431087A1 (en) 2023-03-14 2024-09-18 Sanovel Ilac Sanayi Ve Ticaret A.S. A film coated tablet of sitagliptin or a pharmaceutically acceptable salt thereof
JP2025076633A (ja) 2023-11-02 2025-05-16 沢井製薬株式会社 シタグリプチン製剤及びその保管方法
EP4563143A1 (en) 2023-11-30 2025-06-04 Sanovel Ilac Sanayi ve Ticaret A.S. A bilayer tablet formulation of metformin and sitagliptin comprising antioxidant
EP4563144A1 (en) 2023-11-30 2025-06-04 Sanovel Ilac Sanayi ve Ticaret A.S. A tablet comprising an extended-release formulation for metformin and immediate release formulation comprising sitagliptin

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
GB9324803D0 (en) * 1993-12-03 1994-01-19 Ferring Bv Enzyme inhibitors
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
JP2003514508A (ja) 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ グルカゴン拮抗剤／逆作用剤
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
TR200001728T2 (tr) 1997-11-11 2000-09-21 Ono Pharmaceutical Co., Ltd. Birleşik pirazin türevleri
JP2002513762A (ja) 1998-05-04 2002-05-14 ポイント セラピューティクス， インコーポレイテッド 造血刺激
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de) * 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
FR2780974B1 (fr) 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
GB9906715D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
DE60012721T4 (de) 1999-03-29 2010-09-09 Uutech Ltd., Coleraine Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
WO2000059887A1 (en) 1999-04-02 2000-10-12 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
CN1356977A (zh) 1999-05-17 2002-07-03 诺沃挪第克公司 胰高血糖素拮抗剂/反向激动剂
WO2001023420A2 (en) 1999-09-28 2001-04-05 Bayer Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
AU1916401A (en) 1999-11-12 2001-06-06 Guilford Pharmaceuticals Inc. Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
EP1301187B1 (en) 2000-07-04 2005-07-06 Novo Nordisk A/S Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
DE60316416T2 (de) * 2002-03-25 2008-06-26 Merck & Co., Inc. Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
ATE370141T1 (de) * 2002-10-07 2007-09-15 Merck & Co Inc Antidiabetische heterocyclische beta- aminoverbindungen als inhibitoren von dipeptidylpeptidase
CA2513684A1 (en) * 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

Also Published As

Publication number Publication date
BG108493A (en) 2005-04-30
YU100603A (sh) 2006-05-25
EP1412357B1 (en) 2006-03-22
BRPI0210866B1 (pt) 2016-07-05
US8168637B2 (en) 2012-05-01
HU225695B1 (hu) 2007-06-28
ATE471148T1 (de) 2010-07-15
EA200501805A1 (ru) 2006-06-30
EP2292232B1 (en) 2014-08-20
NO20040021L (no) 2004-01-05
US20170348309A1 (en) 2017-12-07
CN1861077A (zh) 2006-11-15
AU2002320303B2 (en) 2004-10-14
NO2008013I1 (no) 2008-09-08
HRP20031098B1 (en) 2012-03-31
FR07C0041I2 (fr) 2016-09-30
ES2344846T3 (es) 2010-09-08
ZA200309294B (en) 2004-07-22
ES2259713T3 (es) 2006-10-16
IS2964B (is) 2017-02-15
CY2007019I2 (el) 2017-07-12
CY2007019I1 (el) 2009-11-04
ME00439B (me) 2011-12-20
US6699871B2 (en) 2004-03-02
PT1412357E (pt) 2006-07-31
NZ529833A (en) 2005-01-28
CN1290848C (zh) 2006-12-20
EP2226324A1 (en) 2010-09-08
NL300287I1 (nl) 2007-10-01
MXPA04000018A (es) 2004-05-21
US20060270679A1 (en) 2006-11-30
JO2230B1 (en) 2004-10-07
CA2450740A1 (en) 2003-01-16
IL159109A (en) 2007-06-03
MY127961A (en) 2007-01-31
GEP20063734B (en) 2006-01-10
NO2007010I2 (no) 2009-12-14
US20130217695A1 (en) 2013-08-22
US20150359793A1 (en) 2015-12-17
JP2004536115A (ja) 2004-12-02
IL178307A (en) 2010-04-15
AR036114A1 (es) 2004-08-11
CY2008014I1 (el) 2009-11-04
LTC1412357I2 (lt) 2021-01-11
HUS0700005I1 (hu) 2022-01-28
GEP20053734B (en) 2006-01-10
ATE321048T1 (de) 2006-04-15
KR20040010842A (ko) 2004-01-31
US20200206221A1 (en) 2020-07-02
PL196278B6 (pl) 2023-02-13
HUP0401104A2 (hu) 2004-09-28
US7125873B2 (en) 2006-10-24
DE122008000046I1 (de) 2009-02-05
KR100606871B1 (ko) 2006-08-01
LU91470I2 (fr) 2008-10-20
WO2003004498A1 (en) 2003-01-16
NL300357I1 (nl) 2008-10-01
IL159109A0 (en) 2004-05-12
FR07C0041I1 (enExample) 2007-10-19
RS50737B (sr) 2010-08-31
PL196278B1 (pl) 2007-12-31
FR08C0033I2 (fr) 2010-12-31
DE60210093T2 (de) 2006-11-23
HUP0401104A3 (en) 2006-02-28
NL300357I2 (nl) 2009-01-05
LUC91360I2 (enExample) 2020-06-12
EP2292232A1 (en) 2011-03-09
DE60236767D1 (de) 2010-07-29
FR08C0033I1 (enExample) 2008-09-26
CY2008014I2 (el) 2009-11-04
BRPI0210866B8 (pt) 2021-05-25
US8440668B2 (en) 2013-05-14
HK1068882A1 (en) 2005-05-06
DK1412357T3 (da) 2006-07-17
CY1110784T1 (el) 2015-06-10
BR0210866A (pt) 2004-06-29
US20040167133A1 (en) 2004-08-26
EP1625847A1 (en) 2006-02-15
JP3762407B2 (ja) 2006-04-05
SI1412357T1 (sl) 2006-06-30
IS8617A (is) 2007-03-06
DOP2002000438A (es) 2003-01-31
US20100130504A1 (en) 2010-05-27
PE20030654A1 (es) 2003-07-29
ECSP044935A (es) 2004-02-26
NO321999B1 (no) 2006-07-31
IS2218B (is) 2007-03-15
NO2020007I1 (no) 2020-03-19
EP1625847B1 (en) 2010-06-16
NL300287I2 (nl) 2009-04-01
UA74912C2 (en) 2006-02-15
LUC91360I1 (enExample) 2020-04-23
PL367279A1 (en) 2005-02-21
EP1412357A1 (en) 2004-04-28
NO2008013I2 (no) 2011-01-24
DE60210093D1 (de) 2006-05-11
MA27053A1 (fr) 2004-12-20
HRP20031098A2 (en) 2004-06-30
IS7062A (is) 2003-11-28
CN1524082A (zh) 2004-08-25
LTPA2007006I1 (lt) 2020-04-27
CR7235A (es) 2006-05-31
DE122007000056I1 (de) 2007-12-13
EA200400153A1 (ru) 2004-06-24
TWI226331B (en) 2005-01-11
EA006845B1 (ru) 2006-04-28
NO2007010I1 (no) 2007-09-17
BE2007C047I2 (enExample) 2021-06-04
PT1625847E (pt) 2010-08-20
US20030100563A1 (en) 2003-05-29
CA2450740C (en) 2006-02-14
EA012701B1 (ru) 2009-12-30
US20110190308A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
DK1625847T3 (da) Medicinsk anvendelse af tetrahydrotriazolo[4,3-A]pyrazin
NO20024553L (no) Absorberende gjenstand av ±ngangsbuksetype
DE60020518D1 (de) Verwaltung von Benutzerprofilen
PT1242425E (pt) Compostos de n-(5,7-dimetoxi¬1,2,4|triazolo1,5-a|pirimidin-2-il) arilsulfonamida e sua utilizacao como herbicidas
DE60044269D1 (de) Krankenliege
EE200300544A (et) 4-anilinokinoliin-3-karboksamiidid, nende kasutamine ning valmistamine
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
DK1274364T3 (da) Medicinsk implantat
EE05433B1 (et) 4-(2-butlamino)-2,7-dimetl-8-(2-metl-6-metoksprid-3-l)[1,5-a]prasolo-1,3,5-triasiin, selle farmatseutiliselt vastuv?etavad eelravimid v?i farmatseutiliselt vastuv?etavad soolad ning nende kasutamine
DE60103909D1 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate
DE60103054D1 (de) Phenyloxazol-1,4-diazabicyclo[3.2.2]nonanderivate, ihre herstellung und ihre therapeutische verwendung
DE60100621D1 (de) 4-heteroaryl-1,4-diazabicyclo 3.2.2.]nonane, ihre herstellung und ihre therapeutische anwendung
DE50113085D1 (de) Verwendung von Polyamid Mischungen
AU2001263492A1 (en) 21956 and 25856, human aminopeptidases and uses thereof
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
AU2002361697A1 (en) Absorbent article leg cuff configuration
BR0214708B1 (pt) calça absorvente descartável.
AU2003302487A1 (en) Substance which exhibits antiviral and antibacterial activity and is based on derivatives of 2,8-dithioxo-1h-pyrano(2,3d86,5-d')dipyrimidyne and 10-aza-analogue thereof
DE50203525D1 (de) Tetrahydroisochinoline, ihre herstellung und verwendung als schmerzmittel
DK1496904T3 (da) Anvendelse af lægemidler indeholdende N,N'-disubstituerede piperazinforbindelser
PT1326866E (pt) 3,4-di-hidropirido[1,2-a]pirimidinas substituidas
PT1325010E (pt) 3, 4-di-hidropirimido [1,2-a] pirimidinas e 3, 4-di-hidropirazino [1,2-a] pirimidinas substituidas
AU2002361989A1 (en) N,n'-disubstituted piperazine compounds and the use of the same as analgesics
DK1337533T3 (da) Resolvering af trans-7-(hydroxy-methyl)octa-hydro-2H-pyrido-1,2a)pyrazin
DE60221998D1 (de) Herstellung von aminonitrilen